NAT1, N-acetyltransferase 1, 9

N. diseases: 133; N. variants: 9
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 GeneticVariation disease LHGDN Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case-control study. 18365755 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.320 GeneticVariation group LHGDN N-acetyltransferase-1 (NAT1) and N-acetyltransferase-2 (NAT2) are important in the metabolism of aromatic and heterocyclic amine carcinogens that induce prostate tumors in the rat. 12355549 2002
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.320 Biomarker group BEFREE N-acetyltransferase-1 (NAT1) and N-acetyltransferase-2 (NAT2) are important in the metabolism of aromatic and heterocyclic amine carcinogens that induce prostate tumors in the rat. 12355549 2002
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.360 Biomarker disease CTD_human NAT1 and NAT2 are both subject to genetic polymorphism in humans, and molecular epidemiological investigations suggest that NAT1 and/or NAT2 acetylator genotype modifies risk for prostate cancers. 12618593 2003
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 Biomarker disease BEFREE NAT-1 overexpression in clinical breast cancers was confirmed at the mRNA level and immunohistochemical analysis of NAT-1 in 108 breast cancer donors demonstrated a strong association of NAT-1 staining with estrogen receptor-positive tumors. 14517345 2003
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 Biomarker disease BEFREE NAT-1 overexpression in clinical breast cancers was confirmed at the mRNA level and immunohistochemical analysis of NAT-1 in 108 breast cancer donors demonstrated a strong association of NAT-1 staining with estrogen receptor-positive tumors. 14517345 2003
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.400 Biomarker group BEFREE NAT-1 overexpression in clinical breast cancers was confirmed at the mRNA level and immunohistochemical analysis of NAT-1 in 108 breast cancer donors demonstrated a strong association of NAT-1 staining with estrogen receptor-positive tumors. 14517345 2003
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 AlteredExpression disease BEFREE Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. 17973251 2008
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 AlteredExpression disease BEFREE Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. 17973251 2008
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.400 AlteredExpression group BEFREE Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. 17973251 2008
CUI: C0000768
Disease: Congenital Abnormality
Congenital Abnormality 		0.030 Biomarker group BEFREE NAT1 both activates and deactivates arylamine drugs and carcinogens, and NAT1 polymorphisms are associated with increased frequencies of many cancers and birth defects. 18259988 2008
CUI: C0220810
Disease: Congenital defects
Congenital defects 		0.020 Biomarker group BEFREE NAT1 both activates and deactivates arylamine drugs and carcinogens, and NAT1 polymorphisms are associated with increased frequencies of many cancers and birth defects. 18259988 2008
CUI: C0007113
Disease: Rectal Carcinoma
Rectal Carcinoma 		0.010 Biomarker disease BEFREE N-acetyltransferase 1 in colon and rectal cancer cases from an industrialized area. 18569593 2008
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.100 Biomarker disease BEFREE N-acetyltransferase 1 might compete with cytochrome P-450 1A2*1C to increase the colorectal cancer risk in intermediate white meat consumers, whereas the rapid N-acetyltransferase 1 genotype may exert a harmful effect on individuals with high carcinogen exposure. 19273964 2009
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.090 Biomarker disease BEFREE N-acetyltransferase 1 might compete with cytochrome P-450 1A2*1C to increase the colorectal cancer risk in intermediate white meat consumers, whereas the rapid N-acetyltransferase 1 genotype may exert a harmful effect on individuals with high carcinogen exposure. 19273964 2009
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.400 AlteredExpression group BEFREE NAT1 is up-regulated in several cancer types, and overexpression can lead to increased survival and resistance to chemotherapy. 22090474 2012
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 AlteredExpression group BEFREE NAT1 is up-regulated in several cancer types, and overexpression can lead to increased survival and resistance to chemotherapy. 22090474 2012
CUI: C0023531
Disease: Leukoplakia
Leukoplakia 		0.010 GeneticVariation disease BEFREE NAT1 rapid acetylation could not modulate the risk of leukoplakia and cancer (OR=0.9, 95% CI: 0.6-1.3; OR=1.0, 95% CI: 0.7-1.4, respectively). 23168701 2012
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.010 Biomarker disease BEFREE NAT1 emerged as a genetic effect modifier of tobacco smoke exposure in MS susceptibility. 24625537 2014
CUI: C3160887
Disease: Node-positive breast cancer
Node-positive breast cancer 		0.010 Biomarker disease BEFREE NAT1 is a possible prognostic biomarker for lymph node-positive breast cancer. 25528056 2014
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.020 Biomarker group BEFREE NAT1 rapid acetylators showed a 2.8-fold excess risk (95% CI 1.5-5.2) for lymphoma (all subtypes combined). 25689677 2016
CUI: C1332206
Disease: Adult Lymphoma
Adult Lymphoma 		0.020 Biomarker disease BEFREE NAT1 rapid acetylators showed a 2.8-fold excess risk (95% CI 1.5-5.2) for lymphoma (all subtypes combined). 25689677 2016
CUI: C1332979
Disease: Childhood Lymphoma
Childhood Lymphoma 		0.020 Biomarker disease BEFREE NAT1 rapid acetylators showed a 2.8-fold excess risk (95% CI 1.5-5.2) for lymphoma (all subtypes combined). 25689677 2016
CUI: C0279626
Disease: Squamous cell carcinoma of esophagus
Squamous cell carcinoma of esophagus 		0.010 GeneticVariation disease BEFREE NAT1 and NAT2 genetic polymorphisms and environmental exposure as risk factors for oesophageal squamous cell carcinoma: a case-control study. 25886288 2015
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.100 Biomarker phenotype BEFREE N-acetyltransferase 1 (NAT1) is an enzyme that metabolizes carcinogens, which suggests a potential role in breast carcinogenesis. 29339455 2018